- Home
- MBRX
as 10-23-2025 3:56pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 23.5M | IPO Year: | 2016 |
| Target Price: | $5.00 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $3.65 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
GlobeNewswire
a month ago
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Argus Research
4 months ago
Daily – Vickers Top Buyers & Sellers for 06/24/2025
TipRanks
4 months ago
Moleculin Biotech prices 16.08M shares at 37c in public offering
MT Newswires
4 months ago
Top Midday Decliners
MT Newswires
4 months ago
Moleculin Biotech Prices $5.9 Million Offering of Shares, Warrants
GlobeNewswire
4 months ago
Moleculin Announces $5.9 Million Public Offering
GlobeNewswire
4 months ago
Moleculin Participates in Virtual Investor “What This Means” Segment
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.